This is a great interview with CEO Paterson. So nice to have an articulate person leading the company.
“I started to hear anecdotally that the current TAVR devices were calcifying. They’ve been around for about 5 years, so doctors are starting to see that these in situ valves are having some issues, as you would expect, as they’re made from tissues that calcify,” Paterson said. “That led me to think, ‘Well if we already have that part of the problem solved what do we do next?'”
“They’ve built a better mouse trap, for want of a better term. Clearly one that won’t calcify. We’re in a bit of a perfect storm right now,” Paterson said. “When I have a decent amount of IP lodged, I will then be looking to talk to 1 or 2 of the big 4, to look to a co-development deal.”
This is HUGE.
Any speculation on who this will be?
I have two scenarios................
i. Edwards and Medtronic currently control 80% of the market, let's say 40% each. If One of these companies wants to take the lion share of the others or even if they envision taking 90%+ of the entire TAVR market I can see them wanting to do a deal with Wayne and Admedus.
ii. One of the big global healthcare companies other than Edwards or Medtronic who haven't been able to break into the TAVR market for whatever reason. Poor design, poor tissue, problems with FDA.... Could be anything. Doesn't matter. Admedus has the device(delivery system + tissue) so now it's up to you to do everything else (manufacture, supply, marketing etc.) A great proposition for an emerging player.
This is so exciting.
AHZ Price at posting:
26.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)